Skip to main content

Advertisement

Log in

A novel therapeutic option in Cogan diseases? TNF-α blockers

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Cogan’s syndrome is characterized by non-infectious, interstitial keratitis combined with a vestibulo-auditory deficit. Despite therapy with corticosteroids in combination with immunosuppressive agents, relapses occurred in two subjects and the clinical course suggested a progression of the disease. Treatment with anti-TNF-α was started leading to a rapid and sustained clinical remission for over 2 respectively 3 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cogan DG (1945) Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 33:144

    Google Scholar 

  2. Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS (1980) Cogan syndrome: studies in thirteen patients, long-term follow up, a review of the literature. Medicine (Baltimore) 59:426–439

    CAS  Google Scholar 

  3. Vollertsen RS, McDonald TJ, Younge BR, Banks BM, Stanson AW, Ilstrup DM (1986) Cogan’s syndrome: 18 cases and a review of the literature. Mayo Clin Proc 61:344–361

    PubMed  CAS  Google Scholar 

  4. Allen NB, Cox CC, Cobo M, Kisslo J, Jacobs MR, Mc Callum RM, Haynes BF (1990) Use of immunosuppressive agents in the treatment of the severe ocular and vascular manifestations of Cogan’s syndrome. Am J Med 88:296–301

    Article  PubMed  CAS  Google Scholar 

  5. Baumann A, Helbling A, Oertle S, Häusler R, Vibert D (2005) Cogan’s syndrome: clinical evolution of deafness and vertigo in three patients. Otology 262:45–49

    CAS  Google Scholar 

  6. Lundardi C, Bason C, Leandri M, Navone R, Lestani M, Millo E et al (2002) Autoantibodies to inner ear and endothelial antigens in Cogan’s syndrome. Lancet 360:915–921

    Article  Google Scholar 

  7. Arnold W, Gebbers JO (1984) Serum-Antikörper gegen Kornea und Innenohrgewebe beim Cogan-Syndrom. Laryngol Rhinol Otol 63:428–432

    Article  CAS  Google Scholar 

  8. Helmchen C, Arbusow V, Jäger L, Strupp M, Stöcker W, Schulz P (1999) Cogan’s syndrome: clinical significance of antibodies against the inner ear and cornea. Acta Otolaryngol 119:528–537

    Article  PubMed  CAS  Google Scholar 

  9. St. Clair EW, McCallum RM (1999) Cogan’s syndrome. Curr Opin Rheumatolog 11:47–52

    Article  CAS  Google Scholar 

  10. Matteson EL, Tirzaman O, Facer GW, Fabry DA, Kaperbauer J, Beatty CW, McDonald TJ (2000) Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 109:710–714

    PubMed  CAS  Google Scholar 

  11. Riente L, Taglione E, Berrettini S (1996) Efficacy of methotrexate in Cogan’s syndrome. J Rheumatol 23:1830–1831

    PubMed  CAS  Google Scholar 

  12. Kasapcopur OE, Ashraf M, Caliskan S, Arisoy N (2000) Cogan’s syndrome: a rare vasculitis in childhood. J Rheumatol 27:1824–1825

    PubMed  CAS  Google Scholar 

  13. Lipsky PE et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602

    Article  PubMed  CAS  Google Scholar 

  14. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM (2002) Inhibition of the TNF-pathway use of infliximab an etanercept as remission-inducing agents in cases of therapy resistant chronic inflammatory disorders. Swiss Med Wkly 132(29–30):414–422

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Helbling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fricker, M., Baumann, A., Wermelinger, F. et al. A novel therapeutic option in Cogan diseases? TNF-α blockers. Rheumatol Int 27, 493–495 (2007). https://doi.org/10.1007/s00296-006-0252-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-006-0252-y

Keywords

Navigation